Study of JS001 in Participants With Advanced Solid Tumors
Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Listed as NCT02857166, this PHASE1 trial focuses on Solid Tumors and remains completed. Sponsored by Shanghai Junshi Bioscience Co., Ltd., it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Apr 2019 — Nov 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .